Session 10: CLL

119  DEL(13q14.3) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 13Q DELETION ALONE OR NORMAL KARYOTYPE

M. Mian1, A. Rinaldi1, A. A. Mensah1, D. Rossi3, M. Ladetto2, F. Forconi4, R. Marasca5, E. Zucca1, F. Cavalli1, G. Gaidano2, V. Gattei6, E. Cavall1, G. Gaidano2, F. Bertoni1
1Exp. Oncology, IGSI, Bellinzona, Switzerland, 2Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom, 3Medicina V, University of Heidelberg, Heidelberg, Germany, 4German CLL Study Group, Cologne, Germany

Introduction: CLL is the most common adult-onset leukemia in the Western world. The disease has a very heterogeneous natural clinical course and survival after diagnosis can range from months to decades. The most frequent chromosomal aberration is del(13q14), targeting the DLEU2/MIR15A/MIR16B locus. When present as single FISH lesion, it is considered as a good prognosticator. Deletions at 13q14.3 are heterogeneous and an involvement of other transcripts mapped in the region has been reported. Data have been recently presented suggesting a worse outcome for patients having larger deletions (del(13q14.3)).

Aim: To evaluate this observation, we analyzed CLL patients, characterized by FISH as having a normal karyotype or del(13q14.3) alone, with a high density genome-wide DNA array.

Patients and Methods: DNA was extracted from consecutive diagnostic frozen samples diagnosed and treated according to the NCI criteria, in 4 centers and analyzed with Affymetrix Human Mapping 6.0 arrays. Profiles were estimated using circular binary segmentation algorithm using 270 Caucasian HapMap profiles as reference dataset to normalize the CLL DNA profiles.

Results: 3 types of 13q losses were defined. 1, loss of the DLEU2/MIR15A/MIR16B locus alone (58/169 cases, 34%), type 2 comprising also RB1 gene (24/169 cases, 14%) and type 3 extending for 10 Mb, thus beyond these two loci (n=13/169 cases, 8%). A diosomic status 13q locus was present in 74/169 (44%) patients (13q wt). With a median follow-up of 60 months (range 0.2-314), the type of deletion significantly affected the outcome. Patients with larger deletions (type 2 and 3) presented a significantly worse time to treatment (TT) than type 1 patients (p=0.038 and 0.004, respectively). Type 1 and 3 behaved similarly to 13q wt cases, with only type 1 lesions associated with a better TT than 13q wt patients (p=0.022). While type 1 and type 2 lesions did not reach the median overall survival (OS), type 3 had a worse OS than 13q wt (p=0.018). Type 3 cases had significantly less commonly mutated IGHV genes.

Conclusions: Losses targeting a larger number of transcripts, including RB1 and DLEU7, are associated with a worse clinical outcome. These data prompt the need to better characterize the 13q14.3 deletion pattern at diagnosis to make a proper outcome estimate.

120 RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY

P. Hillman1, J. G. Gribben1, G. A. Follows3, D. Milligan1, H. A. Sayatana1, P. Morris1, D. G. Osier1, C. E. Dearden, D. B. Kennedy1, A. R. Pettitt1, K. M. Paterson1, A. Nathawani1, D. Cohen12, R. A. Rawstron14, C. F. Pocock14
1Haematology, St James’s Institute of Oncology, Leeds, United Kingdom, 2Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom, 3Haematology, Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Haematology, Heartlands Hospital, Birmingham, United Kingdom, 5HMD, Leeds General Infirmary, Leeds, United Kingdom, 6Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom, 7Haematology-Oncology Unit, Royal Marsden Hospital, London, United Kingdom, 8Haematology, Leicester Royal Infirmary, Leicester, United Kingdom, 9Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom, 10Haematology, University College London, London, United Kingdom, 11CTRU, University of Leeds, Leeds, United Kingdom, 12HMD, St James’s Institute of Oncology, Leeds, United Kingdom, 13Haematology, Kent and Canterbury Hospital, Canterbury, United Kingdom

Introduction: Rituximab plus fludarabine and cyclophosphamide is now widely used as first-line treatment for medically fit patients with CLL. For less fit patients chlorambucil is commonly used but achieves only modest response rates with few complete responses (CRs); thus more effective regimens are needed. We report the results of a multicentre Phase II study of R-chlorambucil as first-line treatment for CLL.

Methods: 100 patients with previously untreated CLL received six 28-day cycles of rituximab (500mg/m2 Day 1 [575mg/m2/cycle] ) plus chlorambucil (10mg/m2/day Days 1-7). Response data were compared to case-matched data from 200 patients from the chlorambucil-only arm of an earlier UK study (LRF CLL4, 1994–2008) matched 1:2 by Binet stage, IgVH mutation, 11q status by FISH, and age.

Results: Median age was 70 (43–86). The overall response rate (ORR) in all 100 patients was 89% (95%CI 70.8–97.3) with 12 patients (12%) achieving a CR, achieving a CR, with 66% ORR and 6% CR in the case-matched controls (Table). Median PFS was 23.9 months. The regimen was well tolerated – most adverse events were grade 1 or 2.

Conclusions: R-chlorambucil is an effective and well-tolerated treatment for patients with previously untreated CLL, which appears to result in higher response rates than chlorambucil alone. R-chlorambucil is currently being evaluated in a randomised comparison with chlorambucil alone (CLL11).

121 FCR VS AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A COMPARISON OF TWO PROSPECTIVE STUDIES OF THE GCLLSG

P. Dreger1, R. Busch1, S. Stilgenbaurer2, A. Fink2, T. Zenz1, U. Jaeger2, S. Jung2, J. Schetelig2, M. Hensel2, W. Knauf2, A. Bühler1, D. Weikler1, M. Kneba1, M. Schmitt1, H. Döhner2, M. Hallek1
1Medicine V, University of Heidelberg, Heidelberg, Germany, 2German CLL Study Group, German CLL Study Group, Cologne, Germany

A recent prospective randomized trial has suggested that autologous stem cell transplantation (autoSCT) doubles progression-free survival (PFS) and treatment-free survival in comparison to conventional 1st-line chemotherapy without rituximab for CLL (Michallet et al, Blood 2010). In order to set this data into perspective with the current 1st-line gold standard, the fludarabine-cyclophosphamide-rituximab (FCR) regimen, we have compared retrospectively patients from the prospective GCLLSG CLL3 trial (autoSCT; 1996–2002) with the FCR arm of the GCLLSG CLL8 trial (2003–2006; Hallek et al, Lancet 2010). Eligible were all patients from CLL3 and CLL8 (FCR) who were <60 years, were chemotherapy-naïve, and had complete central genomic work-up available. Patients with del17p were excluded. The primary objective of the study was to assess if autoSCT has superior PFS and time to specific relapse (TTRT) over FCR.

Results: 110 of 169 patients from the CLL3 trial and 126 of 408 patients from the CLL8 (FCR) trial met the inclusion criteria. AutoSCT and FCR patients were well matched for age, time from diagnosis to study entry, serum thymidine kinase levels, FISH risk group, and IGHV status (unmutated 64% vs 68%). However, autoSCT patients had significantly higher beta2-microglobulin serum levels (3.3 vs 2.7 mg/dl) and were significantly more likely to be in Binet A stage at study entry (15% vs 5%). With a median observation time of surviving patients of 8.3 and 4.7 years, respectively, PFS of the autoSCT group was significantly longer than that of the FCR group (median 6.2 vs 4.3 years, p 0.009). This effect remained significant after multivariate adjustment for potential confounders (hazard ratio (HR) for FCR 1.66 (95%CI 1.11–2.5)). However, TTRT and OS were not different between autoSCT and FCR (4-year TTRT 75% vs 77%, HR for FCR 1.03, p 0.91; and 4-year OS 86% vs 90%, HR for FCR 1.32, p 0.39). Subgroup analyses did not reveal a significant TTRT benefit for autoSCT in any Binet, IGHV and FISH subset and 4-year OS was not different between autoSCT and FCR (4-year NRM 7% vs 4%, p 0.68).

Conclusions: Although these results confirm that autoSCT is a highly effective 1st-line treatment for CLL, no significant clinical benefit of autoSCT over FCR could be observed.
122 THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND TOLERABLE IN PATIENTS WITH POOR-RISK CLL: INTERIM RESULTS FROM A PHASE IB/II STUDY.


1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Department of Leukemia, Stanford University School of Medicine, Stanford, United States, 3Vallumere Valley Cancer Inst. Ctr, US Oncology, Springfield, OR, United States, 4Med center, New York Presbyterian Hospital Cornell, New York, United States, 5Dept, Sarah Cannon, Nashville, United States, 6Dept of Medicine, University of Vermont and Fletcher Allen Health Care, Burlington, United States, 7US Oncology, Texas Oncology, Tyler, United States, 8Pathology, The Ohio State University, Columbus, United States, 9Division of Hematology, The Ohio State University, Columbus, United States, 10Clinical development, Pharmacycica, Inc, Sunnyvale, United States

Introduction: Bruton’s tyrosine kinase (Btk) is a downstream mediator of B-cell receptor (BCR) signaling. PCI-32765 (P) is a potent, irreversible inhibitor of Btk, causing inhibition of survival signaling, cellular chemotaxis and homing in CLL cells ex vivo. We report the interim results of an ongoing Phase Ib/II trial of P in treatment-naïve (TN) or relapsed/ refractory (R/R) CLL.

Methods and Patients: This Phase Ib/II study is evaluating the safety and efficacy of P in 2 cohorts of CLL: 1) 265 years old with TN disease, and 2) R/R disease following at least 2 prior treatment regimens, one of which must have included fludarabine. P was administered PO QD for 28-day cycles until disease progression (PD). Doses of 420mg and 840mg QD were evaluated in separate cohorts of R/R patients; only the 420mg QD dose was evaluated in TN patients. Clinical response was evaluated according to standard criteria.

Results: 39 patients have been enrolled to the 420mg cohorts of the study (12 TN, 27 R/R). Median number of prior treatment regimens in R/R pts was 3 (2-10). 87% of pts had at least one poor-risk molecular feature: del17p 30%, del11q 21%, unmutated IgVH 70%. The majority of AEs have been mild in severity and not clearly related to P. Grade 3 AEs potentially related to P have occurred in 31% of pts. Grade 3/4 neutropenia and thrombocytopenia have occurred in ≤5% of pts. No hepatic or renal AEs have been reported.

In evaluable pts with lymphopenopathy (LN), the rate of nodal response (LNR: 250% reduction in target lesions) is 89% (25/28 pts). A transient increase in absolute lymphocyte counts (ACL) occurred in 75% of pts with measurable LN. LNR was similar in patients with or without poor-risk molecular features. Platelet counts have improved in 9/13 pts (69%) with baseline thrombocytopenia. At a median follow-up of 4 months, 34/39 pts remain on P. Reasons for discontinuation: pt decision n=2, AE n=2, PD n=1. Overall response by CLL IWG criteria and progression-free survival will be updated.

Conclusions: P is highly active with minimal toxicity in pts with either TN or R/R CLL, including molecular-poor-risk pts.

123 SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP


1IIIrd Medical Department with Haematology, Medical Oncology, Private Medical University Hospital, Salzburg, Austria, 2Institute for Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany, 3Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany, 4Department of Internal Medicine III, University of Ulm, Ulm, Germany, 5IIIrd Medical Department, Hanusch Hospital, Vienna, Austria

Background: T-cell prolymphocytic leukemia (T-PLL) is a very rare and generally refractory disease with a poor prognosis. The scarcity of available systemic trial data has largely prevented uniform therapeutic guidelines. To address improvement and prolongation of responses in T-PLL, we designed a prospective, multicenter phase-II study that adds a fludarabine-based polychemotherapy to the established most active single substance, namely alemtuzumab.

Patients and Methods: This multicenter phase-II trial evaluated response, survival, and toxicity of a novel regimen (FMC-A) in 25 patients with T-PLL (9 previously treated, 16 ECOG performance score ≤ 1). Induction by fludarabine, mitoxantrone, and cyclophosphamide (FMC, up to 4 cycles) was followed by alemtuzumab (A) consolidation (12 weeks, 30mg IV, 3x/week).

Results: The overall response rate (ORR) after FMC was 68%, comprising 6 complete remissions (CR) and 11 partial remissions (PR). Alemtuzumab consolidation, given to 21 patients, increased the ORR to 95% (10 CR; 10 PR). Median PFS for all 25 patients was 11.9 months (93.4-14.6 CI 95%), median PFS was 12.9 months for patients in CR as compared to 10.4 months for patients achieving a PR as their best response. Median OS was 17.1 months (12.1-21.1 CI 95%). There were no significant differences in ORR, OS, and PFS between the subgroups of previously treated and treatment-naive patients. PFS tended to be shorter for patients with high-level TCL1 encoprotein expression (p=0.05). The most frequent grade 3/4 toxicity under FMC-A was myelosuppression. Only in the 21 patients treated with alemtuzumab a total of 12 CMV reactivations were observed, which were asymptomatic in 3/12, while 9/12 experienced a clinically relevant CMV infection.

Conclusion: Sequential FMC-A induces response rates associated with survival that are among the best reported in T-PLL. It thus is a very effective and also safe regimen, but nearly all patients, regardless of quality of response eventually relapse. Therefore, a key issue remains the search for the most optimal front-line regimen consisting of an alemtuzumab backbone to bridge towards a potentially curative allogeneic stem cell transplantation.

124 CLADRIBINE GIVEN SUBCUTANEOUSLY FOR FIVE DAYS HAS EQUIVALENT CELLULAR EFFICACY TO AND LOWER TOXICITY THAN CLADRIBINE GIVEN FOR SEVEN CONSECUTIVE DAYS IN PATIENTS WITH HAIRY CELL LEUKEMIA


1Ematologia e Trapezi, Università di Siena - ASLUS, Siena, Italy, 2Clinica Ematologica, DIFIM, Udine, Italy, 3Ematologia, Ospedali Riuniti, Bergamo, Italy, 4Ematologia, Azienda Ospedaliera Reggio Calabria, Reggio Calabria, Italy, 5Ematologia, Azienda Ospedaliera Catanzaro, Catanzaro, Italy, 6Dip. Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy, 7Department of Haematology and Medical Oncology, University of Bologna, Italy, 8Unità Operativa Ematologia, Ospedale Ca’ Foncello, Treviso, Italy, 9Ematologia, Ospedale Civile, Alessandria, Italy, 10Hematology, European Institute of Oncology, Milan, Italy, 11Division of Hematology, AO, Ascoli Piceno, Italy, 12Division of Hematology, IRCC, University of Eastern Piedmont, Novara, Italy, 13Hematology, AO Università Careggi, Florence, Italy, 14Hematologia, Azienda Ospedaliera, Cuneo, Italy

Introduction: Cladribine (2CdA) given 0.1 mg/kg/day for 7 consecutive days intravenously or subcutaneously is very effective in HCL, although it may cause infections in a high proportion of patients.

Material and methods: In the Italian multicentre ICHGLCH2004 clinical trial, toxicity and efficacy of sc2CdA given 0.1mg/kg/die for 5 (arm A) or 7 consecutive days (arm B) was prospectively evaluated in centrally verified classic HCL requiring first treatment. Study endpoints were i) early grade 3-4 toxicity, ii) response to treatment, iii) treatment free interval (TFI), iv) relapse free survival (RFS), v) time to second tumor (TTST) and vi) overall survival (OS). TFI and RFS were measured as the time elapsed from sc2CdA initiation to second treatment because of new progression or failure to sc2CdA in all patients and in responsive patients only, respectively.

Results: 148 classical HCL entered the study. Clinical and laboratory parameters prior to treatment were equally balanced in the two arms. Overall hematological toxicity was no different among the two treatment arms. However, a higher non hematological toxicity was observed in arm B (p=0.019). Non haematological toxicity was mainly represented by infections/FUO which were more frequent in arm B (17/71, 23.9%) than in arm A (8/77, 10.4%, p=0.028) and that resulted in a hospitalization rate higher in arm B (20/71, 28.2%) than in arm A (9/77, 11.7%, p=0.012). One hundred forty patients (94.6%) had a beneficial response. Responses were equivalent in the two arms, with 74/77 (97%, 95%CI 95%) and 70/71 (99%, 95%CI 98%) of patients achieving CR or PR, respectively. However, no differences of TFI, RFS, TTST and OS were observed in the 2 arms.

Conclusions: This study indicates that sc2CdA given at 25% reduced doses (0.3 mg/kg) has equivalent activity and significantly lower toxicity than sc2CdA at standard doses (0.7 mg/kg). The reduced infection rates and hospitalization rates of sc2CdA have equivalent activity and significantly lower toxicity than sc2CdA at standard doses (0.7 mg/kg).